Shares of IDEXX Laboratories (NASDAQ:IDXX) traded 0.04 points or 0.05% higher at $88.92.The total intraday money flow for the shares came in at a disappointing $(-1.81) million. The total upticks amounted to $7.68 million and the total downticks were approximately $9.48 million, with the up/down ratio of 0.81. On a different note, the shares have seen 0.93% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $0 million in upticks and an outflow of $1.79 million in downticks. The up/down ratio for the block was found to be 0. The net money flow for the block transaction was $(-1.79) million.
Currently the company Insiders own 2.79% of IDEXX Laboratories shares according to the proxy statements. Institutional Investors own 96.3% of IDEXX Laboratories shares. During last six month period, the net percent change held by insiders has seen a change of -4.76%. On the companys insider trading activities,The director of Idexx Laboratories Inc /De, End William T sold 4,924 shares at $85.87 on May 5, 2016. The Insider selling transaction had a total value worth of $422,824. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
IDEXX Laboratories (NASDAQ:IDXX) : On Monday heightened volatility was witnessed in IDEXX Laboratories (NASDAQ:IDXX) which led to swings in the share price. The stock opened for trading at $88.6 and hit $89.43 on the upside , eventually ending the session at $88.92, with a gain of 0.05% or 0.04 points. The heightened volatility saw the trading volume jump to 521,685 shares. The 52-week high of the share price is $91.9448 and the company has a market cap of $7,961 million. The 52-week low of the share price is at $61.58 .
Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Credit Suisse maintains its rating on IDEXX Laboratories (NASDAQ:IDXX). The rating major has initiated the coverage with outperform rating on the shares. The Analysts at Credit Suisse raises the price target from $80 per share to $85 per share. The rating by the firm was issued on April 13, 2016.
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Company sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy, and Other. Its Products and services include point-of-care veterinary diagnostic products; veterinary reference laboratory diagnostic and consulting services; practice management systems and services, and digital imaging systems; biological materials testing, laboratory animal diagnostic instruments and services; diagnostic, health-monitoring and food safety testing products for livestock, poultry and dairy; products that test water for microbiological contaminants, and point-of-care electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.